Lysophosphatidylcholine: Potential Target for the Treatment of Chronic Pain

Abstract

The bioactive lipid lysophosphatidylcholine (LPC), a major phospholipid component of oxidized low-density lipoprotein (Ox-LDL), originates from the cleavage of phosphatidylcholine by phospholipase A2 (PLA2) and is catabolized to other substances by different enzymatic pathways. LPC exerts pleiotropic effects mediated by its receptors, G protein-coupled signaling receptors, Toll-like receptors, and ion channels to activate several second messengers. Lysophosphatidylcholine (LPC) is increasingly considered a key marker/factor positively in pathological states, especially inflammation and atherosclerosis development. Current studies have indicated that the injury of nervous tissues promotes oxidative stress and lipid peroxidation, as well as excessive accumulation of LPC, enhancing the membrane hyperexcitability to induce chronic pain, which may be recognized as one of the hallmarks of chronic pain. However, findings from lipidomic studies of LPC have been lacking in the context of chronic pain. In this review, we focus in some detail on LPC sources, biochemical pathways, and the signal-transduction system. Moreover, we outline the detection methods of LPC for accurate analysis of each individual LPC species and reveal the pathophysiological implication of LPC in chronic pain, which makes it an interesting target for biomarkers and the development of medicine regarding chronic pain.

Impact of feeding dried distillers’ grains with solubles diet on microbiome and metabolome of ruminal and cecal contents in Guanling yellow cattle

“…Our results showed that resveratrol was upregulated by DDGS diet in the “Longevity regulating pathway,” and may have a positive effect on the prevention of intestinal inflammation. Lysophosphatidylcholine (LysoPC) is a pro-inflammatory lipid and is considered as a key marker in pathological conditions ( Ren et al, 2022 ). Another choline metabolite phosphatidylcholine (PC) can mediates proliferative growth and programmed cell death ( Saito et al, 2022 ).…”

Developing A Baseline Metabolomic Signature Associated with COVID-19 Severity: Insights from Prospective Trials Encompassing 13 U.S. Centers

“…However, the effect of LysoPC molecules on inflammation remains controversial. Both proinflammatory [23,25] and anti-inflammatory [26][27][28][29][30][31][32] effects of the LysoPC molecules have been reported previously. Our results are in agreement with other studies showing that LysoPC levels are lower in patients with more severe COVID-19 [26,28,29].…”

Serum-based metabolomics reveals the mechanism of action of isorhynchophylline in the intervention of atherosclerosis in ApoE−/− mice

“…24 PC is converted to LPC by lecithin cholesterol acyltransferase (LCAT). 25 LPC is one of the key active components of ox-LDL, 26 which specifically regulates the activation of T-lymphocytes as evidenced by the increased secretion of OX40L and interferon-gamma, which may promote the inflammatory response to AS. 27 The geometry of the LPC structure is determined by the saturation of the acyl chain, which is deleterious to its properties and activity in terms of saturation and length.…”